News

ETN tops Q1 estimates as revenues jump 17% and EPS rises 3%; it has lifted 2026 adjusted EPS guidance and sees 9-11% organic growth.

Uber will report first quarter earnings before the bell on Wednesday as the ride-hailing giant looks to prove its profit growth story is intact, even as its costly autonomous ambitions grow.

Unity is facing pressure from weak outlook and AI threats. Yet Wedbush Securities signals confidence and eyes potential upside into earnings.

Softer-than-expected U.S. commercial revenues appeared to outweigh raised sales guidance.

VTRS gears up to report Q1 results as import alerts, regional pressures and growth in key brands shape expectations ahead of May 7 release.

PayPal tops Q1 estimates as TPV jumps 11% and revenue climbs, signaling strong platform momentum despite operating margin pressure and softer engagement trends.

CoreWeave Rockets Into Earnings With High-Stakes AI Demand Test

Heavy activity on both call and put sides

AMPX heads into Q1 results with strong revenue growth expectations, fueled by battery demand, NDAA tailwinds and expanding market traction.

ATI beats Q1 EPS on strong aerospace and defense demand, but revenues miss estimates as pricing and product mix lift profitability.

APTV tops Q1 estimates with higher earnings and revenues, but regional weakness and margin pressure temper gains after its EDS spin-off.

Horizon Quantum posted its first earnings report since going public more than a month ago. Horizon’s operating loss swelled to $6.5 million from $4.7 million last year. Horizon, like its pure-play peers, has yet to turn a profit.

Shopify Drops After Strong Results: Guidance Clouds Growth Story

Gartner beats Q1 EPS estimates as contract value rises and costs ease, lifting the 2026 EPS and free cash flow guidance despite lower revenues.

Applied Optoelectronics reports Q1 2026 earnings on May 7, guiding $150M-$165M revenues as CATV and data center demand stay strong.

Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.

Shopify Inc (TSX:SH., NYSE:SHOP) shares fell sharply on Wednesday, dropping 13.5% after the company reported mixed first quarter 2026 results that paired strong revenue growth with a sizeable loss and guidance that largely met expectations rather than exceeding them. For the quarter ended...

Fiserv beat Q1 earnings estimates on a 17 cents per share tax boost, but revenues miss as margins slide and Clover GPV hits $324B.

Rockwell Automation tops Q2 earnings estimates with strong volume, margin gains and organic growth, prompting a higher FY26 view amid broadening demand.

ORLA nears Q1 results as earnings estimates surge and gold output jumps, with Musselwhite gains offsetting weaker Camino Rojo performance.

SEZL will report Q1'26 results on May 6; consensus targets $132.2M in revenues and EPS of $1.24 as subscriptions, engagement and AI support growth.

Ariel Investments, an investment management company, released its “Ariel Focus Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund reported strong first-quarter performance for its Ariel Focus Fund, which gained 7.30%, significantly outperforming both the S&P 500’s -4.33% return and the Russell 1000 Value Index’s 2.10% gain amid […]

AXON heads into Q1 earnings with strong TASER, body camera and software demand expected to fuel growth despite rising costs.

Moby summary of Shopify Inc.'s Q1 2026 earnings call

Moby summary of Rockwell Automation, Inc.'s Q2 2026 earnings call

CMI beat Q1 2026 estimates as Power Systems and data-center power demand lifted margins, even as Engine and Components sales fell.

Moby summary of PayPal Holdings, Inc.'s Q1 2026 earnings call

HWM heads into Q1 earnings with strong aerospace demand expected to drive growth, though supply-chain issues and transport softness linger.

Moby summary of Fiserv, Inc.'s Q1 2026 earnings call

Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.